Recombinant BST2 antibody

Catalog No. ABIN8093017

This Rabbit Monoclonal antibody specifically detects BST2 in WB, ELISA and IHC. It exhibits reactivity toward Human.

Quick Overview for Recombinant BST2 antibody (ABIN8093017)

Target: BST2 (Bone Marrow Stromal Cell Antigen 2 (BST2))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This BST2 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Clone: BST2-13682R

Product Details anti-BST2 Antibody

Purpose: BST2 Antibody / CD317

Immunogen: Recombinant BST2 protein was used as the immunogen for the CD317/BST2 antibody.

Isotype: IgG, kappa

Application Details

Application Notes: 1. Optimal dilution of the CD317/BST2 antibody should be determined by the researcher.

2. This CD317/BST2 antibody is recombinantly produced by expression in CHO cells.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.05 % BSA, 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: CD317/BST2 antibody with sodium azide - store at 2 to 8oC, antibody without sodium azide - store at -20 to -80oC.

Target Details for BST2

Target: BST2 (Bone Marrow Stromal Cell Antigen 2 (BST2))

Alternative Name: BST2

Background: CD317 antibody, also known as BST2 antibody, recognizes Bone marrow stromal antigen 2, an interferon-inducible type II transmembrane protein encoded by the human BST2 gene located on chromosome 19p13.2. CD317 is widely referred to in the literature as Tetherin and HM1.24. CD317 localizes to the plasma membrane, endosomes, and the trans-Golgi network, where it functions as an antiviral restriction factor and immune regulatory protein. CD317 antibody is commonly used in research investigating innate immunity, interferon responses, and viral host defense mechanisms.

Bone marrow stromal antigen 2 contains a short N-terminal cytoplasmic tail, a single-pass transmembrane domain, an extracellular coiled-coil region, and a C-terminal glycosylphosphatidylinositol anchor. This dual-anchor topology enables CD317 to tether budding virions to the host cell membrane, physically restricting viral particle release. Expression of BST2 is strongly upregulated by type I interferons, linking its function to antiviral signaling pathways. CD317 antibody supports studies of host-virus interactions and interferon-mediated immune responses.

CD317 is expressed in immune cell populations including B lymphocytes, plasmacytoid dendritic cells, activated T cells, and monocytes, and can also be detected in epithelial tissues under inflammatory conditions. In addition to its antiviral role, BST2 has been implicated in NF-kappaB activation and regulation of cytokine production, highlighting its broader involvement in immune signaling networks. CD317 antibody is therefore frequently applied in research examining inflammatory pathways and immune cell activation.

Beyond infectious disease research, CD317 expression has been reported in multiple myeloma and other hematologic malignancies, where HM1.24 serves as a cell surface marker in research settings. Clone BST2/13682R is a recombinant rabbit monoclonal antibody developed to recognize CD317 for research applications. This antibody targets Bone marrow stromal antigen 2 in research settings and supports studies of antiviral defense, immune regulation, and cancer biology.

UniProt: Q10589

Pathways: Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response